Please login to the form below

Not currently logged in
Email:
Password:

Medicare

This page shows the latest Medicare news and features for those working in and with pharma, biotech and healthcare.

Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US

Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US

For Aduhelm and similar therapies, the policy will set national guidance on how Medicare treats these particular drugs in the future. ... The officials also added that trials must be demographically representative of Medicare patients suffering with

Latest news

More from news
Approximately 6 fully matching, plus 159 partially matching documents found.

Latest Intelligence

  • The US celebrates five years of biosimilars on the market – a look to the past, present and future The US celebrates five years of biosimilars on the market – a look to the past, present and future

    Between 2012 and 2016, annual spending on biologic drugs in the US nearly doubled, with unit prices accounting for 56% of the spending increase within Medicare Part D and 20% in ... In Medicare Part B, legislation could be passed to encourage physician

  • Eliminating pharmaceutical rebates, is this déjà vu? Eliminating pharmaceutical rebates, is this déjà vu?

    Due to consolidation in the industry, most prescription drug benefits, including Medicare Part D benefits, are administered by several significant PBMs. ... Completely eliminating Medicare Part D rebates within PBMs is not essential for lowering the

  • The global antibiotic crisis: a 2020 perspective The global antibiotic crisis: a 2020 perspective

    2020. It seeks to incentivise drug developers by changing the way Medicare reimburses hospitals for treating patients with bacterial infections.

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    Others call for more involvement from equally relevant and powerful government bodies, such as Congress, the Centers for Medicare and Medicaid Services, the US Patent and Trademark Office and the US

  • The Golden Goose The Golden Goose

    Yet another market-friendly idea that enjoys broad support among patient advocacy groups is allowing Medicare to negotiate with drugmakers. ... Unfortunately, on closer inspection, this pathway also presents difficulties. To negotiate effectively,

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....